The folate receptor (FR) is a recognised biomarker for tumour cells due to its overexpression
on a large number of tumours. Consequently, the FR has been exploited by many diagnostic …

The folate receptor (FR) is a potentially useful biological target for the management of many
human cancers. This membrane protein binds extracellular folates with very high affinity …

Cancer therapies that exploit targeting ligands to deliver attached cytotoxic drugs selectively
to malignant cells are currently receiving significant attention. While antibody-targeted drugs …

The development of specialized nanoparticles for use in the detection and treatment of
cancer is increasing. Methods are being proposed and tested that could target treatments …

The folate receptor (FR) is a confirmed tumor-associated antigen that binds folate and folate–
drug conjugates with very high affinity and shuttles these bound molecules inside cells via …

The membrane-bound folate receptor (FR) is overexpressed on a wide range of human
cancers, such as those originating in ovary, lung, breast, endometrium, kidney and brain …

In normal tissues, the expression of folate receptors is low and limited to cells that are
important for embryonic development or for folate reabsorption. However, in several …

In order to avoid the toxicities associated with prescription drug use today, we have explored
novel methods for delivering drugs selectively to pathologic cells, thereby avoiding the …

Targeted delivery combined with controlled release of drugs has a crucial role in future of
personalized medicine. The majority of cancer drugs are intended to interfere with one or …

Targeted delivery via selective cellular markers can potentially increase the efficacy and
reduce the toxicity of therapeutic agents. The folate receptor (FR) has two glycosyl …